97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
20 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs011200009
06/11/202006/11/2020vedolizumab-4026A study to evaluate the relationship between the pharmacokinetics of vedolizumab in the colon tissue and in the serum concentrations, alpha4beta7 integrin receptor occupancy and the efficacy in subjects with moderately to severely active ulcerative colitis and treated by vedolizumab IV - vedolizumab-4026 Subjects with UCVedolizumab 300 mg is administered at Week 0, 2, 6 and every 8 weeks thereafter. Treatment duration is 46 weeks.Fujiya MikihiroFernandez Jovelle;Takeda Pharmaceutical Company Limited (Takeda)Pending>= 20age old<= 80age oldBoth30Phase 4Japan
2ChiCTR2000035497
2020-10-012020-08-13A multicenter, randomized, controlled trial of Qingyu Powder in the treatment of mild to moderate active ulcerative colitisA multicenter, randomized, controlled trial of Qingyu Powder in the treatment of mild to moderate active ulcerative colitis ulcerative colitisExperimental group:Qingyusan;Control group:Mesalazine;Shuguang Hospital affiliated to Shanghai University of traditional Chinese MedicineNULLPendingBothExperimental group:40;Control group:40;China
3ChiCTR2000032498
2020-09-012020-04-30Human experimental study on the effect of probiotics combined with prebiotics on ulcerative colitis: a randomized double-blind controlled trialHuman experimental study on the effect of probiotics combined with prebiotics on ulcerative colitis Ulcerative colitisExperimental group:Probiotics and prebiotics;placebo group:maltodextrin;Capital Medical UniversityNULLPendingBothExperimental group:15;placebo group:15;China
4ChiCTR2000033953
2020-07-012020-06-18Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)Effect of the probiotic on symptoms in patients with ulcerative colitis (UC) Ulcerative colitisPlacebo group:Maltodextrin;experimental group 1:Lactobacillus plantarum CCFM8610;experimental group 2:Lactobacillus plantarum N13;experimental group 3:Lactobacillus casei CCFM1059;Jiangnan UniversityNULLPendingBothPlacebo group:20;experimental group 1:20;experimental group 2:20;experimental group 3:20;China
5ChiCTR1900025900
2019-12-012019-09-13Efficacy of Herbal enema prescriptionII(DHEP II) in the treatment of mild or moderate active symptoms of ulcerative colitis:A multicenter prospective randomized control clinical trial.Efficacy of Herbal enema prescriptionII(DHEP II) in the treatment of mild or moderate active symptoms of ulcerative colitis:A multicenter prospective randomized control clinical trial. Ulcerative colitisExperimental group:Mesalazine+DHEP II;control group:Mesalazine+Compound Huangbai lotion;Nanjing Hospital of Chinese MedicineNULLPendingBothExperimental group:200;control group:100;Phase 3China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6ChiCTR1900024086
2019-08-012019-06-24Modified Chinese Medicine Granule in the Treatment of Ulcerative Colitis in the Remission Phase: Study Protocol for a Series of N-of-1 Randomized, Double-Blind, Controlled TrialsModified Chinese Medicine Granule in the Treatment of Ulcerative Colitis in the Remission Phase: Study Protocol for a Series of N-of-1 Randomized, Double-Blind, Controlled Trials Ulcerative Colitisintervention period:Modified Chinese Medicine Granule and Mesalazine placebo;control period:Mesalazine and Modified Chinese Medicine Granule placebo;The First Affiliated Hospital of Guangzhou University of Chinese MedicineNULLPending1875Bothintervention period:10;control period:10;N/AChina
7ChiCTR1900024591
2019-07-222019-07-18Clinical evaluation for traditional Chinese medicine in the treatment of severe active ulcerative colitisClinical evaluation for traditional Chinese medicine in the treatment of severe active ulcerative colitis Ulcerative colitisTCM Group:Prednisone+New Wumeiwan Formula;Convenience medicine Group:Prednisone+Mesalazine Enteric-coated tablets (Salofalk);Combined Group:Prednisone+New Wumeiwan Formula+Mesalazine Enteric-coated tablets(Salofalk);Peking University First HospitalNULLPending1865BothTCM Group:40;Convenience medicine Group:40;Combined Group:40;China
8EUCTR2018-003364-31-PL
(EUCTR)
15/03/201923/01/2019A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.A Phase II randomized, placebo controlled, double-blind, 4 arms dose-ranging study to evaluate the efficacy and safety of SHR0302 compared to placebo in patients with moderate to severe active Ulcerative Colitis. Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: SHR0302
INN or Proposed INN: Pending
Reistone Biopharma Company LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
152Phase 2United States;Poland;Ukraine;China
9ChiCTR1900021229
2019-02-182019-02-02The role of fecal calprotectin in the treatment of patients with clinically quiescent ulcerative colitisThe role of fecal calprotectin in the treatment of patients with clinically quiescent ulcerative colitis Ulcerative colitisIntervention group:Increasing the dose of mesalamine according to fecal calprotectin levels;Control group:Maintaining current dosage of mesalamine;Beijing Friendship Hospital, Capital Medical UniversityNULLPendingBothIntervention group:74;Control group:74;China
10ChiCTR1800019676
2018-12-012018-11-22Diagnostic Value of probe-based Confocal Laser Endomicroscopy Score for assessment of numosal healing of ulcerative colitisDiagnostic Value of probe-based Confocal Laser Endomicroscopy Score for assessment of numosal healing of ulcerative colitis: a single center, prospective cohort study ulcerative colitisGold Standard:Histopathological examination;Index test:1, Gland density (grade)
2. Gland morphology (grade)
3. Vascular changes (grade);
Peking University First HospitalNULLPending1880BothTarget condition:40;Difficult condition:0China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11ChiCTR1800016438
2018-06-302018-06-01Clinical research of flupentixol-melitracen and mesalazine on ulcerative colitisClinical research of flupentixol-melitracen and mesalazine on ulcerative colitis ulcerative colitiscontrol:mesalazine 1 po qid;observation group:mesalazine 1 po qid; flupentixol-melitracen 1pill po tid;Guiyang 1st People's HospitalNULLPending1575Bothcontrol:30;observation group:30;China
12JPRN-UMIN000030988
2018/02/0101/02/2018Open-label, randomized, two-parallel-arm, single center study to designed to evaluate azathioprine versus adalimumab after induction of tacrolimus in refractory ulcerative colitis therapy Ulcerative ColitisInduce azathioprine and continue maintenance therapy by azathioprine
Induce adalimumab and continue maintenance therapy by adalimumab
Sakura Medical Center, Toho universityNULLPending15years-oldNot applicableMale and Female53Not applicableJapan
13ChiCTR-IPR-17010306
2017-02-012017-01-01Effects of probiotics on intestinal microecological reconstruction in patients with ulcerative colitisEffects of probiotics on intestinal microecological reconstruction in patients with ulcerative colitis Ulcerative colitisGroup A:Mesalazine combined with placebo; Group B:Methalazine combined with probiotics;Group C:Probiotics combined with placebo;Normal control group:Blank control;Affiliated Hospital of Inner Mongolia Medical UniversityNULLPending18BothGroup A:30; Group B:30;Group C:30;Normal control group:30;China
14JPRN-UMIN000019066
2015/09/2518/09/2015An open label randomized controlled trial of combination therapy of Adalimumab and GMA for intractable ulcerative colitis Ulcerative colitisAdministration of Adalimumab 160 mg at baseline, 80 mg at 2 weeks and 40 mg every 2 weeks.
In addition to Adalimumab Therapy, co-treatment of GMA 3times a week up to 2 weeks
Sakura Medical Center,Toho universityNULLPending20years-oldNot applicableMale and Female58Not applicableJapan
15JPRN-UMIN000018745
2015/09/0101/09/2015The Efficacy of Enternal Nutrition in Active Ulcerative Colitis Patients with Hypoalbuminemia ,during Infliximab Therapy ulcerative colitisAdministration of Infliximab and enteral nutrition
Administration of Infliximab
Nagoya University Graduate School of Medicine, Department of Gastroentrology and hepatologyNULLPending15years-old75years-oldMale and Female40Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16ChiCTR-IPR-15005760
2015-01-122015-01-02Steroid-dependent ulcerative colitis pathogenesis of complex multi-center alternative medicine therapy, randomized, controlled clinical studySteroid-dependent ulcerative colitis pathogenesis of complex multi-center alternative medicine therapy, randomized, controlled clinical study ulcerative colitisTCM Group:Oral Chinese medicine Qinchang Lianyang Granule + Guanchang Fang granule;Control:Azathioprine;Affiliated Hospital of Nanjing University of Chinese MedicineNULLPending1865BothTCM Group:60;Control:60;I (Phase 1 study)China
17JPRN-UMIN000013546
2014/06/0131/03/2014The effect ofgrepefruit juice on the patients with autoimmune diseases taking tacrolimus rheumatoid arthritis, lupus nephritis, polymyositis/dermatomyositis with interstitial pneumonia, ulcerative colitistake a glass of grapefruit juice every day
do not take grapefruit juice
Department of Rheumatology and Clinical Immunology, Kyoto University HospitalNULLPending16years-old80years-oldMale and Female20Not applicableJapan
18JPRN-UMIN000013033
2014/02/0101/02/2014Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis. Ulcerative colitisStudy start - 14 weeks:5mg/kg of Infliximab for 0.2.6.14 week, respectively ( initial administration day with 0 weeks)Department of Internal Medicine,Juntendo UniversityNULLPending20years-oldNot applicableMale and Female30Not selectedJapan
19JPRN-UMIN000013266
2013/05/0125/02/2014Randomized controlled study comparing 1% of Dermacrin A ointmentwith 0.033% of Guaiazulene ointment for patients with perianal delmatitis after total colectomy ulcerative colitis, familial adenomatous polyposis1% of Dermacrin A ointment
0.033% of Guaiazulene ointment
Mie University Graduate School of Medicine, Gastrointestinal and Pediatric SurgeryNULLPending20years-oldNot applicableMale and Female30Not applicableJapan
20JPRN-JapicCTI-184217
22/11/2018A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (I6T-MC-AMBG)A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (I6T-MC-AMBG) Ulcerative ColitisIntervention name : LY3074828
INN of the intervention : mirikizumab
Dosage And administration of the intervention : intravenous injection, Subcutaneous injection
Control intervention name : Placebo
INN of the control intervention : Placebo
Dosage And administration of the control intervention : intravenous injection, Subcutaneous injection
Eli Lilly Japan K.K.NULLpending1880BOTHPhase 3NULL